Clinical trial · Observational
Biomarkers in Autoimmune Disease of Nervous System
Biomarkers of Neurological Autoimmune Diseases
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Neurological autoimmune diseases are a group of disorders characterized by the abnormal immune response attacking the nervous system, including the brain, spinal cord and peripheral nerves. These diseases exhibit high heterogeneity, diverse clinical presentations, and are challenging to diagnose and manage due to a lack of effective treatments. In this study, the investigators will recruit eight kinds of autoimmune diseases of nervous system including Neuromyelitis Optica Spectrum Disorder (NMOSD), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), idiopathic inflammatory myopathy (IIM), and multiple sclerosis (MS), autoimmune encephalitis (AE), Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD). Through this study, the investigators aim to discover biomarkers with high sensitivity, specificity, and stability, which can support early diagnosis, disease monitoring, and personalized treatment for neurological autoimmune diseases, thereby improving the quality of life and prognosis for patients.
Conditions
Conditions (11)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Disseminated Encephalomyelitis | — | UNRESOLVED | — |
| Autoimmune Diseases | — | UNRESOLVED | — |
| Autoimmune Diseases of the Nervous System | — | UNRESOLVED | — |
| Autoimmune Encephalitis | — | UNRESOLVED | — |
| Chronic Inflammatory Demyelinating Polyradiculoneuropathy | — | UNRESOLVED | — |
| Guillain-Barre Syndrome | — | UNRESOLVED | — |
| Idiopathic Inflammatory Myopathies | — | UNRESOLVED | — |
| Multiple Sclerosis | — | UNRESOLVED | — |
| Myasthenia Gravis | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| biomaker levels | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- autoimmune disease
- description
- clinical diagnosis with autoimmune disease of central nervous system
- interventionNames
- Diagnostic Test: biomaker levels
- label
- health control
- description
- age- and sex-matched control individuals
- interventionNames
- Diagnostic Test: biomaker levels
Primary outcomes (1)
- measure
- All-cause mortality
- timeFrame
- 10 years
- description
- Death during the follow-up in every single reason
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical diagnosis with autoinflammatory diseases of the nervous system, including: Neuromyelitis Optica Spectrum Disorder (NMOSD), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), idiopathic inflammatory myopathy(IIM), multiple sclerosis (MS), autoimmune encephalitis (AE), Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), ect al. * sex and age-matched healthy individuals Exclusion Criteria: * Known history of primary immunodeficiency (innate or acquired). * Patients with severe central nervous system, pulmonary, or other systemic infections. * Patients with secondary central nervous system demyelinating lesions, such as those caused by vasculitis, systemic lupus erythematosus, and Sjögren's syndrome. * Patients with vascular (including hemorrhagic and ischemic), hereditary metabolic, neoplastic, or toxic diseases. * Pregnant or lactating women.
References
Publications (3)
- RESULTMcPherson RC, Anderton SM. Adaptive immune responses in CNS autoimmune disease: mechanisms and therapeutic opportunities. J Neuroimmune Pharmacol. 2013 Sep;8(4):774-90. doi: 10.1007/s11481-013-9453-9. Epub 2013 Apr 9. PMID 23568718
- RESULTStenager E. A global perspective on the burden of multiple sclerosis. Lancet Neurol. 2019 Mar;18(3):227-228. doi: 10.1016/S1474-4422(18)30498-8. Epub 2019 Jan 21. No abstract available. PMID 30679041
- RESULTSolomon AJ, Arrambide G, Brownlee WJ, Flanagan EP, Amato MP, Amezcua L, Banwell BL, Barkhof F, Corboy JR, Correale J, Fujihara K, Graves J, Harnegie MP, Hemmer B, Lechner-Scott J, Marrie RA, Newsome SD, Rocca MA, Royal W 3rd, Waubant EL, Yamout B, Cohen JA. Differential diagnosis of suspected multiple sclerosis: an updated consensus approach. Lancet Neurol. 2023 Aug;22(8):750-768. doi: 10.1016/S1474-4422(23)00148-5. PMID 37479377